Navigation Links
Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial
Date:3/12/2008

eting and look forward to this pivotal assessment of HD-02 as a treatment for slowing Huntington's disease for which there currently is no approved treatment," stated Belinda Tsao Nivaggioli, CEO and Chairman of Avicena. "We are also pleased to further strengthen our on-going relationship with Dr. Steven Hersch, Dr. Diana Rosas, and Dr. Bernard Ravina. We look forward to working with the NCCAM, a Division of NIH, and the Orphan Products Division through their sponsorship of this trial."

"We are very enthusiastic about the study results of HD-02 to date and excited to be advancing it into a Phase III trial," stated lead investigator Dr. Steven Hersch. "This Phase III study will evaluate whether HD-02 can slow the progression of Huntington's disease, and pending positive results, may provide a much needed treatment option to Huntington's patients."

ABOUT HD-02

HD-02 is a novel and proprietary drug candidate for the treatment of Huntington's disease (HD). HD-02 has been granted orphan drug designation in the U.S. Results from a Phase II clinical trial of HD-02, led by Dr. Steven Hersch of Massachusetts General Hospital, were published in the January 24, 2006 issue of Neurology and showed that HD-02 suppressed a Huntington's disease marker. Some researchers have linked this oxidative marker as a measure of cellular injury. Earlier preclinical studies performed by Dr. Flint Beal of Cornell Medical Center and Dr. Robert Ferrante of Boston University, showed that HD-02 has significant neuroprotective effects, such as improved movement, reduced neuropathology, and prolonged survival.

ABOUT HUNTINGTON'S DISEASE

Huntington's disease is a progressive neurodegenerative disease caused by a defective gene that is often inherited from parent to child. This genetic defect causes a widespread deterioration of neurons in those parts of the brain that are responsible for controlling cognitive, emotional and motor functions. This progressive deteriora
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
2. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
3. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
4. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
5. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
6. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
11. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... NASA’s MESSENGER has just celebrated its 10 year ... have one of its latch valves, V27200-818, operating onboard ... investigation of the planet Mercury. It is only the ... provided a vast amount of information and images of ... utilize solenoids that also include permanent magnets to maintain ...
(Date:9/17/2014)... 17, 2014 The Alliance ... a multi-stakeholder non-profit collaborative building a global system ... research, today announced Phase 3 of its Site ... , Amir H. Kalali, Vice-President, Global Head, Neuroscience ... President, Compliance and Quality Integration (CQI) Consulting will ...
(Date:9/16/2014)... 16, 2014 This report analyzes the worldwide markets ... Software, Hardware, and Biocontent. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014  Biocom, ... life science community, recognizes the 9 th ... to the value of IT technologies in improving our ... California is one of the world,s most ... from EHRs to mobile health applications to genomic testing ...
Breaking Biology Technology:Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23Biocom Recognizes National Health IT Week 2
... Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ("Oncolytics") ... Patent 7,374,752 entitled "Reovirus for the Treatment ... compositions,which comprise various recombinant reoviruses., "This ... protection for,reovirus compositions in the United States," ...
... of Two-Phase Examination of U.S. Asthma Control, RESEARCH ... half of adult Americans with asthma and more than ... nationally representative survey do,not have their disease well controlled, ... at the International Conference of the American,Thoracic Society meeting ...
... 20 CellCyte Genetics,Corporation (CellCyte) (OTC Bulletin ... H. Traverse, M.D., FACC, FAHA, to its ... is an interventional,cardiologist with the Minneapolis Heart ... in cardiovascular stem cell clinical,trial research., ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent 2Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows 2Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows 3CellCyte Genetics Corp. Appoints Jay H. Traverse to Scientific Advisory Board as Clinical Consultant 2CellCyte Genetics Corp. Appoints Jay H. Traverse to Scientific Advisory Board as Clinical Consultant 3
(Date:9/16/2014)... Philadelphia, PA, September 16, 2014 Schizophrenia is associated ... A growing body of research suggests that the relationship ... effort by patients to use nicotine to self-medicate symptoms ... new study, published in the current issue of ... authors found that the level of nicotine receptors in ...
(Date:9/16/2014)... are responsible for practically all vital functions in ... forward signals, transport particular substances and control immune ... proteins do not function independently of each other, ... examine the protein networks, you find many similarities ... from TUM,s Chair of Plant Systems Biology. "Some ...
(Date:9/15/2014)... microbes influence processes from digestion to disease resistance. Despite ... terrestrial ecosystems on the planet, more is known about ... Smithsonian scientists and colleagues working on Panama,s Barro Colorado ... tree were home to more than 400 different kinds ... contained more than 7,000 different kinds. , Bacteria in ...
Breaking Biology News(10 mins):Smoking and schizophrenia linked by alterations in brain nicotine signals 2Good networkers make prime targets 2Smithsonian scientists discover tropical tree microbiome in Panama 2
... flowers has been recreated by mathematicians at The University of ... the University of Cambridge to create a mathematical model of ... in flowering plants and the role it may play in ... as you alter the angle you view it from. It ...
... French and German . ... Scientists have been able to reconstruct, for the first ... tetrapods, the earliest four-legged animals. High-energy X-rays and a new ... of the 360 million year old fossils in exceptional detail ...
... quickly than the supply of honey bees, the dominant ... pollination represents a way of increasing crop yield without ... study recently published in the Proceedings of ... 2013) 1, shows that the pollination effectiveness of honey ...
Cached Biology News:How does your garden glow? 2Scientists reassemble the backbone of life with a particle accelerator 2Scientists reassemble the backbone of life with a particle accelerator 32 new studies show why biodiversity is important for pollination services in California almond 2
EDG-6 (1)...
...
...
... Comments: Ab-1 stains tumor cells of embryonal ... type of germ cell tumors like seminoma. Glandular ... are positive. Luminal and endocrine cells of stomach ... breast are also positive. Epitope: Carbohydrate ...
Biology Products: